Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases-Reference-Cited by-同舟云学术

Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases

Published:2008-12 Issue:12 Volume:32 Page:1927-1930
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Santana-Davila Rafael,Tefferi Ayalew,Holtan Shernan G.,Ketterling Rhett P.,Dewald Gordon W.,Knudson Ryan A.,Steensma David P.,Chen Dong,Hoyer James D.,Hanson Curtis A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference8 articles.

1. Efficacy of lenalidomide in myelodysplastic syndromes;List;N Engl J Med,2005

2. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome;Melchert;Leukemia,2007

3. Treatment of deletion 5q acute myeloid leukemia with lenalidomide;Lancet;Leukemia,2007

4. Lenalidomide therapy in myelofibrosis with myeloid metaplasia;Tefferi;Blood,2006

5. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions;Tefferi;Leukemia,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-09

2. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms;Medicina;2021-08-09

3. Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a “grey zone” combination of myelodysplastic and myeloproliferative features?;Haematologica;2019-09-26

4. Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature;Frontiers in Oncology;2018-02-19

5. Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy;Mediterranean Journal of Hematology and Infectious Diseases;2016-10-20